肺癌筛查背景下戒烟干预的优化随机临床试验:CASTL研究
CASTL优化随机临床试验在美国17个肺癌筛查(LCS)站点纳入758名50至80岁正在吸烟且计划接受LCS的参与者,随机分配至16种戒烟干预组件组合。各组件间差异无统计学意义,价值效率最高的组合为损失框架信息+尼古丁贴片+含片(预期戒烟率30%,平均成本287.41美元);仅增益框架信息为低成本替代方案(戒烟率13%,成本51.29美元)。
要点
- LCS场景是提供循证戒烟治疗的重要机会。
- 损失框架信息联合尼古丁贴片与含片为价值效率较高的组合。
- 仅增益框架信息成本更低,可作为低成本替代选项。
核心结论
- 在LCS背景下,损失框架信息联合尼古丁贴片与含片是预期戒烟率与成本权衡下价值效率最高的干预组合。
- 整合联合尼古丁替代治疗与简短吸烟危害沟通是改善戒烟结局的有前景、可行选择。
研究设计与样本
- 优化随机临床试验(CASTL),在美国17个LCS站点开展。
- 纳入758名50至80岁、计划接受LCS且正在吸烟的参与者,随机分配至16种戒烟治疗组件组合。
- 组件包括增强标准照护、动机性访谈、尼古丁贴片/含片和信息框架;主要结局为6个月随访时自我报告的戒烟。
主要发现
- 入组时约5%参与者无戒烟意愿,59%正在考虑戒烟,38%已在改变吸烟行为。
- 79%报告醒后30分钟内吸烟,提示尼古丁依赖程度高。
- 各干预组件间无显著差异;损失框架信息+尼古丁贴片+含片预期戒烟率30%、平均成本287.41美元。
- 仅增益框架信息的低成本组合戒烟率13%、成本51.29美元。
临床怎么用
- 在LCS场景中可考虑将联合尼古丁替代治疗与简短吸烟危害信息沟通整合入戒烟服务。
- 资源有限时可选择仅增益框架信息的低成本方案。
- 未来需评估该组合的实施效果并探索可扩展的实施策略。
局限性
- 主要结局为自我报告戒烟。
- 各干预组件间比较无显著差异。
- 研究在美国LCS站点开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chest . 2026 Jul 8:S0012-3692(26)00944-X. doi: 10.1016/j.chest.2026.06.042. Online ahead of print. ABSTRACT BACKGROUND: Approximately 50% of the estimated 14 million people eligible for lung cancer screening (LCS) currently smoke. Gaps in knowledge regarding optimal tobacco treatment interventions in the context of LCS remain. RESEARCH QUESTION: What is the most value-efficient, evidence-based combination of tobacco treatment component(s) for people seeking LCS who smoke? STUDY DESIGN AND METHODS: Cessation and Screening to Save Lives (CASTL) is an optimization randomized clinical trial conducted at 17 LCS sites in the US. Eligible participants 50 to 80 years of age, scheduled for LCS, and currently smoking were randomized to 1 of 16 combinations of tobacco treatment components: enhanced standard care, motivational interviewing, nicotine patch/lozenge, and message framing. The primary outcome was self-reported abstinence at 6-month follow-up. The cost of each combination of components was estimated as a function of time and resources. RESULTS: Of the 758 participants at enrollment, about 5% of participants were not interested in quitting, 59% were considering quitting, and 38% already were making changes in their smoking. Most (79%) reported smoking within 30 minutes of waking, indicating a high nicotine dependence. Although there were no significant differences among the intervention components, the most value-efficient intervention with respect to expected abstinence was loss-framed messaging, nicotine patch, and lozenge (expected abstinence rate, 30%; mean cost, $287.41). Among the less-costly combinations, a value-efficient alternative included gain-framed messaging only (abstinence, 13%; cost, $51.29). INTERPRETATION: Our results show that LCS provides a compelling opportunity to provide evidence-based tobacco treatment to individuals at risk for lung cancer. Integrating combination nicotine replacement therapy and brief communication about the harms of smoking is a promising value-efficient, feasible option for improving cessation outcomes. Future trials should evaluate the effectiveness implementation of this promising package and examine scalable strategies for implementation of tobacco use treatment in LCS settings. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: 03315910; URL: www. CLINICALTRIALS: gov. PMID: 42419585 | DOI: 10.1016/j.chest.2026.06.042
引用
- PubMed 顶刊 · 肺结节与肺癌筛查:An Optimization Randomized Clinical Trial to Identify an Effective, Efficient Smoking Cessation Intervention in the Context of Lung Cancer Screening: Cessation and Screening to Save Lives
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。